📋 What this guide covers: the four business models for branded ECG electrode manufacturing (OEM / ODM / private label / joint development) and which fits which buyer; a four-tier service ladder; nine critical decisions before signing an OEM contract; how regulatory ownership works across the U.S., EU, Brazil, China and Australia; the typical project timeline from inquiry to first shipment; nine common pitfalls for first-time private-label distributors; and an honest 8-question self-assessment for whether private-label manufacturing fits your business yet.
❌ This guide does NOT cover buying ready-made compatible electrodes for direct hospital sale (see the OEM Compatible ECG Electrodes Guide, written for hospital-direct buyers — a different audience from this brand-owner guide), broader supplier-evaluation criteria (see How to Evaluate ECG Electrode Suppliers), or the detailed regulatory-verification protocol (see the FDA/ISO/CE Compliance Guide).
🎯 Best for: international medical-supply distributors moving from agency to private label; emerging-market agents with brand resources but no manufacturing; hospital groups and GPOs evaluating in-house brand programs; medical-device startups without factory capability; cross-border e-commerce platforms launching electrode SKUs; and existing branded suppliers seeking backup OEM capacity.
⚠️ Educational disclaimer. This article is for distributor, brand-owner and procurement education on private-label and OEM ECG electrode manufacturing. It is not legal, regulatory, or commercial advice for any specific transaction. MOQ ranges, pricing tiers and timeline figures are typical industry references, not specific MedLinket quotations — actual terms depend on the SKU set, customization depth, destination market and commercial relationship. Regulatory ownership of 510(k) clearances, CE certificates and regional registrations carries legal consequences in every market — consult qualified medical-device regulatory counsel before structuring any OEM agreement.
📌 TL;DR
Private-label and OEM ECG electrode programs can let distributors capture materially more gross margin than agency arrangements, lock in customer relationships, and step out of price-war dependence on principal brands. But they work only for distributors meeting four pre-conditions: enough volume to clear MOQ economics (an industry rule of thumb is roughly 50,000 pieces/month), regulatory-registration capability in the destination market, a cash-flow runway to carry first-batch inventory, and a customer-service operation that can handle quality complaints directly. This guide covers the four manufacturing models, a four-tier service ladder, nine pre-contract decisions, the project timeline, and a readiness self-assessment.
The single biggest pitfall: regulatory registration must complete before product reaches the warehouse — many first-time launches stall because the product lands but cannot legally be sold yet.
A Middle Eastern medical distributor represented a European ECG electrode brand for eight years. Annual volume reached two million pieces, but gross margin sat around 18% — the same as in year three. Every renewal was a fight to hold price, and the principal kept lifting the wholesale floor.
In year nine the distributor launched its own private label ECG electrodes line. Within a few years: similar volume, substantially higher gross margin, and lower customer churn, because local hospital buyers had begun accepting the distributor's own brand as a category specification. (Illustrative composite, not a specific MedLinket client — outcomes vary widely by market.)
That is the structural opportunity in disposable ECG electrode private label. This guide walks through the decision framework, the manufacturing-model choice, and the nine most consequential pre-contract decisions that determine whether the move succeeds or stalls.
📚 Part of MedLinket's ECG Electrode cluster. For the parent overview start with the ECG Electrodes Complete Buyer's & Clinical Guide. For the regulatory deep-dive behind the "regulatory ownership" decisions below, see the FDA/ISO/CE Compliance Guide.
1. Why distributors move to private label ECG electrodes
Short answer: disposable ECG electrodes are one of the higher private-label-penetration categories in hospital consumables — driven by mature manufacturing, regulatory predictability and meaningful margin headroom. But the move from agency to private label is not free; it requires capability upgrades that not every distributor has, and this guide makes that distinction explicit.
Four commercial drivers
- Margin headroom. Agency arrangements typically run on thinner gross margin; private-label programs, at adequate volume, can run materially higher — the gap is widest in markets with limited local supply. Treat the exact figures as market-specific.
- Customer-relationship lock. Procurement that has standardized on your private-label SKU resists switching even when competitors discount, because brand standardization creates inventory and clinical-workflow inertia that protects renewals.
- Pricing autonomy. Agency relationships are exposed to the principal's wholesale-price decisions; private-label distributors set their own pricing strategy and respond to local conditions on their own schedule.
- Multi-factory leverage. A private-label brand can source from more than one OEM factory, improving negotiating leverage and supply-chain resilience versus single-source agency.
Who should NOT move to private label
An honest filter — not every distributor benefits, and the move costs working capital, time and attention. Consider staying with agency arrangements if:
- Monthly volume is well below the ~50,000-piece industry rule of thumb — MOQ economics work against you.
- You don't have regulatory-registration capability or a service partner who does — destination-market registration can take 3–12 months.
- You don't have a customer-service operation — quality complaints become your problem, not the principal's.
- You have less than a few years of category experience — connector types, AAMI EC12 margins and biocompatibility requirements take time to learn.
The full self-assessment is in Section 8.
2. OEM vs ODM vs private label vs joint development
Short answer: the four models differ in who owns the product design and how much customization is involved. The terminology is widely conflated in trade press, but the legal and commercial implications of each are distinct.
| Model | Design ownership | What you provide | What the factory provides | Best fit |
|---|---|---|---|---|
| Pure OEM | Buyer owns | Complete product specifications, materials list, possibly tooling | Manufacturing capacity, quality control | Established brands with their own R&D and IP |
| ODM | Factory owns | Brand identity, packaging design, sales channel | Product design, manufacturing, QC | Most distributors and emerging brands |
| Private label | Factory owns | Brand name and logo only | Everything else, using existing product line | Distributors seeking fastest entry with minimal customization |
| Joint development | Shared / negotiated | Market insight, clinical requirements, partial funding | R&D execution, regulatory capability, manufacturing | Larger brand owners pursuing differentiated products |
Why most distributors should start with private label or ODM, not pure OEM
Pure OEM requires you to own the product design — the engineering specifications, the ISO 10993 biocompatibility reports on the specific formulation, the AAMI EC12 performance data, the predicate-device chain for a 510(k) submission, and often the tooling. For most distributors that is unnecessary overhead. ODM and private label leverage the factory's existing regulatory portfolio (510(k), CE, NMPA) while still allowing brand differentiation on packaging and presentation. Joint development is appropriate only when you have a specific differentiated clinical requirement the factory's existing portfolio cannot meet.
💡 Terminology note. "OEM ECG electrodes" and "private label ECG electrodes" are often used interchangeably in conversation. In a contract, what matters is two explicit answers: who holds the design IP, and who holds the regulatory clearance in each market. Both need to be settled regardless of the label on the cover page.
3. The 4-tier service ladder
Short answer: OEM ECG electrode offerings are usefully structured as four progressive tiers, from minimal-customization brand relabeling through full joint development with custom regulatory submissions. The tier should match the distributor's volume, regulatory capability and timeline tolerance.
Brand-only relabeling
- What changes
- Customer brand name and logo on existing factory packaging.
- Product specification
- Standard MedLinket V0014 / V0015 SKUs, unchanged.
- Regulatory pathway
- Factory holds the 510(k) / CE / NMPA; customer receives a Letter of Authorization where required.
- Typical MOQ (industry reference)
- ~50,000–100,000 pieces per SKU.
- Timeline (signing → first shipment)
- ~30–45 days.
- Cash-flow profile
- Lowest — no tooling investment, fastest revenue.
- Best for
- First-time private-label distributors testing market acceptance.
Packaging customization
- What changes
- Pouch material, pack size, count per pouch, multi-language IFU, custom carton design.
- Product specification
- Standard SKUs; only packaging is customized.
- Regulatory pathway
- As Tier 1; packaging changes typically don't trigger new regulatory submissions.
- Typical MOQ (industry reference)
- ~100,000–300,000 pieces per SKU.
- Timeline
- ~45–60 days.
- Cash-flow profile
- Moderate — packaging tooling and minimum print runs.
- Best for
- Distributors with established presence seeking packaging differentiation.
Product micro-customization
- What changes
- Within-platform choices — size mix, snap material (metal vs carbon), structure (offset vs center-post), backing material — all selected from the existing validated platform.
- Product specification
- Customer-specified configuration of validated components.
- Regulatory pathway
- Most configurations sit under existing 510(k) and CE; some may need a regulatory amendment.
- Typical MOQ (industry reference)
- ~500,000–1,000,000 pieces across the SKU set.
- Timeline
- ~60–90 days for validated configurations; longer if an amendment is needed.
- Cash-flow profile
- Higher — multiple SKU production runs.
- Best for
- Established private-label brands extending their portfolio without full joint-development cost.
Joint development
- What changes
- Custom adhesive formulation, custom gel chemistry, novel structural design, or other product-level innovation.
- Product specification
- Co-developed with MedLinket R&D; specifications jointly owned per agreement.
- Regulatory pathway
- New ISO 10993 biocompatibility testing; new 510(k) submission likely; CE technical-file update; NMPA new-product registration if applicable.
- Typical MOQ (industry reference)
- 1,000,000+ pieces with a multi-year commitment.
- Timeline
- ~9–18 months including regulatory cycles.
- Cash-flow profile
- Highest — co-funding R&D, biocompatibility testing and regulatory submission.
- Best for
- Established brands with a specific differentiated requirement and a 2–3 year roadmap.
✅ Recommended progression. Most successful private-label brand owners begin at Tier 1 to validate market acceptance and operational fit, graduate to Tier 2 once the brand is established, and consider Tier 3 only after sustained volume per SKU. Tier 4 joint development is appropriate only when there is a specific clinical requirement no existing product satisfies — not as a "premium upgrade" of Tier 3.
4. 9 critical decisions before signing an OEM contract
Short answer: the OEM contract is not one decision but nine inter-related ones that together determine commercial viability, regulatory exposure and long-term flexibility. Settle each explicitly before signing, not "later."
1Product strategy: which SKUs to carry
Start narrow. In most adult-monitoring markets the best-sellers are the Φ50 mm round metal-snap, the 70.5 × 55 mm offset metal-snap, and the Φ30 mm pediatric. Add a carbon-snap (V0015 radiolucent) variant only in markets where cath-lab and imaging-frequent ICU together make up a significant share of monitoring volume.
Resist launching 10–20 SKUs at once — each consumes inventory cash, regulatory effort and sales-training time. Three to five SKUs at launch is the sweet spot; expand after the initial portfolio shows sustained performance.
2OEM factory selection: minimum hard criteria
| Criterion | Minimum requirement |
|---|---|
| ISO 13485:2016 | Required, scope explicitly covering ECG electrode manufacturing |
| FDA 510(k) | Required if exporting to the U.S. |
| CE under MDR 2017/745 | Required if exporting to the EU; with a Notified Body number |
| AAMI EC12 lot-level test reports | Required — numerical values, not just "compliant" |
| Export experience | Broad multi-country footprint (a proxy for regulatory-adaptation maturity) |
| Production capacity | Ample reserve capacity beyond your planned volume, to support scaling |
For the full supplier-evaluation methodology — 12 criteria across six categories, red-flag patterns, RFP scoring weights and a 30–60 day roadmap — see How to Evaluate ECG Electrode Suppliers.
3MOQ and pricing-tier negotiation
MOQ depends on customization depth. Industry-typical ranges: Tier 1 ~50,000–100,000 pieces/SKU; Tier 2 ~100,000–300,000; Tier 3 ~500,000+; Tier 4 1,000,000+ with a multi-year commitment. Pricing follows volume tiers, and in practice the deepest discounts come from multi-year commitments rather than single-order size — factories trade price for capacity-utilization predictability. (All figures are industry references; request a specific quotation for your SKU set and market.)
4Packaging and brand-design responsibility
| Item | Customer | Factory |
|---|---|---|
| Brand name, trademark, logo | ✅ | — |
| Packaging design files (AI / PSD) | ✅ | Templates provided |
| Print proofing | Approval | Production |
| UDI barcode allocation | Brand prefix | Implementation on packaging |
| Multi-language IFU translation | ✅ | Templates provided |
| Carton structural design | Specification choice | Production |
5Regulatory ownership across destination markets
⚠️ This is the decision new private-label distributors most often get wrong. Regulatory ownership has different default structures by market:
- United States (FDA 510(k)): either the manufacturer or the brand owner can be the 510(k) holder. The most cost-effective approach for new brands is usually for the manufacturer to hold the 510(k) and provide a Letter of Authorization to the brand owner, who acts as importer of record.
- European Union (MDR 2017/745): manufacturer responsibility is non-transferable; the manufacturer name appears on the labeling and in EUDAMED. Non-EU manufacturers must designate an EU Authorized Representative (EC REP), and brand owners typically partner with an EC REP service.
- Brazil (ANVISA): a local legal entity is required as the certificate holder — establish a subsidiary or partner with a local registration holder.
- China (NMPA): a local legal entity is required; brand owners typically register through a Chinese partner acting as the certificate holder.
- Australia (TGA): the sponsor (brand owner or local agent) must be Australian-resident.
MedLinket supports OEM partners with 510(k) Letters of Authorization, CE technical-file documentation and ISO 10993 reports — but who holds the certificate in each market is the brand owner's decision, with significant tax, customs and liability implications. For the verification protocol — how Letters of Authorization work, how to verify a Notified Body, what documentation to demand — see the Compliance Guide.
6Sterile vs non-sterile portfolio strategy
Sterile-coded variants (the "-S-" suffix) carry a modest per-piece premium over non-sterile equivalents but unlock NICU, OR, cath-lab and imaging-frequent ICU channels that non-sterile cannot serve. Most successful private-label brands run a two-line strategy: non-sterile for general-ward and Holter volume, sterile for premium clinical channels at higher per-piece margin.
7Lead time and capacity reservation
- Sample lead time: roughly 5–10 working days for existing SKUs.
- First commercial order: ~30–45 days including packaging customization.
- Repeat runs: ~20–30 days.
- Rush capacity: requires an advance annual capacity-reservation agreement.
For brands committing to steady monthly volume, an annual capacity reservation with minimum monthly draws is worth negotiating — it typically improves pricing versus spot ordering and protects against capacity squeezes in peak seasons.
8Quality clause and complaint-response framework
The quality clause should specify:
- A lot-level Certificate of Analysis with each shipment, including AAMI EC12 numerical values and a biocompatibility batch reference.
- Tiered defect-rate handling with explicit thresholds for who absorbs cost at each level.
- Complaint response: a fast acknowledgment window and a defined root-cause-analysis turnaround.
- Adverse-event traceability: batch trace from lot number to manufacturing record within a defined window.
- Minimum shelf life on receipt: typically a large majority of the 2-year shelf life remaining for international shipments.
A serious manufacturer signs all of these without resistance; pushback on any of them signals future dispute risk.
9Exit and intellectual-property terms
Often overlooked at signing, frequently the most contentious at contract end. Specify:
- Contract duration: e.g. 2–3 years initial with 1-year renewals.
- Tooling and brand-asset ownership: Tier 1–2 typically use factory tooling; Tier 3–4 may involve customer-funded tooling with ownership specified.
- Inventory clearance on contract end: who absorbs unsold work-in-progress, finished goods and packaging.
- Non-compete / exclusivity: the manufacturer agrees not to private-label the same SKU configuration to your direct competitors in your defined territory for the term plus a tail period.
- IP rights on joint development: for Tier 4 specifically — co-ownership, exclusive license, or buyout structure.
5. Why MedLinket as your OEM ECG electrode manufacturer
MedLinket has been a focused biopotential-signal specialist since 2004. It began OEM work in its earliest years, moved into its own-brand distribution around 2010, and was listed on China's New Third Board (NEEQ) in 2015 — described in company materials as the first listed company in the Chinese monitoring-consumables sector. Since around 2022 it has run a dual-track strategy of in-house brand plus OEM/ODM partnerships, with the stated goal of supporting partner brands rather than competing with them in their served markets.
Four core OEM capabilities
1. Full product-line OEM coverage
MedLinket's OEM ECG electrode offerings span the main disposable electrode series:
- Hypoallergenic sterile series (low-allergy hydrophilic PSA + EO sterilization, 5+5-piece pouches).
- Hypoallergenic non-sterile series (low-allergy hydrophilic PSA, bag-and-carton packaging).
- Standard series (cost-efficient general-monitoring formulation).
- Offset (eccentric), center-post, carbon-snap and metal-snap structural variants across the V0014 / V0015 platform.
The platform covers the standard six sizes — Φ25, Φ30, Φ42, Φ50 mm round, plus 50.5 × 35 and 70.5 × 55 mm rectangular — in metal-snap (V0014) and carbon-snap (V0015) materials, sterile and non-sterile. Packaging configurations include 5+5-piece sterile pouches, 25/bag and 250/carton for non-sterile round, and 20/bag and 400/carton for non-sterile rectangular variants.
2. Strong performance margins (AAMI EC12)
MedLinket's registration/laboratory test values for the disposable platform sit well inside the AAMI EC12 limits, and are available on a lot-level basis with each OEM shipment:
| Parameter | AAMI EC12 limit | MedLinket tested value |
|---|---|---|
| AC impedance (average) | ≤ 2,000 Ω | ~109 Ω |
| DC offset voltage | ≤ 100 mV | ~4.11 mV (voltage change) |
| Combined offset instability & noise | ≤ 150 μV (p-p) | within limit (e.g. max voltage ~49.5 μV p-p) |
These are general platform test values from MedLinket registration/laboratory documentation (methodology available on request), not a per-SKU or clinical claim — request the lot-level EC12 report for the specific configuration you are evaluating.
3. Self-developed technology assets
- Patent CN202120112524.5 — the eccentric (offset) thin-neck FPC structural design, a granted utility-model patent. It moves the connector off-center to reduce lead-wire force reaching the gel-skin interface; in MedLinket internal bench pull-testing across 0°–90°, the offset design withstood roughly double or more the pull force of a center-post snap before disconnection (internal bench data, not a clinical claim). Available for OEM licensing in defined territories.
- Self-developed hydrophilic pressure-sensitive adhesive — a proprietary formulation positioned for sweat tolerance and reduced skin sensitization; ISO 10993-5/-10/-23 validated. (The low-allergy benefit is a design positioning to confirm against the IFU and test reports, not a blanket clinical guarantee.)
- Self-developed conductive gel — a semi-solid hydrogel optimized for stable 24–48 hour wear.
- EO sterilization capability — validated under EN ISO 11135 with SAL 10⁻⁶, supporting the sterile-coded ("-S-") variants for OR, NICU and cath-lab use.
MedLinket also holds multiple patents and software copyrights spanning structural design, materials and external appearance (the eccentric-electrode structural patent CN202120112524.5 is the most directly relevant to OEM electrode partners).
4. Global export & regulatory footprint
- Product registrations including 33 NMPA Class II in China, plus FDA 510(k) clearances, CE marking under MDR 2017/745, and registrations across MHRA (UK), ANVISA (Brazil), TGA (Australia) and PMDA (Japan).
- Quality system: ISO 13485:2016, ISO 9001:2015 and MDSAP (covering FDA, Health Canada, ANVISA, TGA and PMDA).
- Dual self-owned manufacturing sites: Shenzhen (HQ) and Shaoguan.
- A broad validated platform — on the order of 10,000+ product types across 2,800+ molds — supporting rapid SKU-set customization within the existing portfolio.
- Active export to over 110 countries, with 14 countries recording annual sales above USD 1 million.
A note on brand compatibility. MedLinket electrodes are designed to be compatible with major monitor brands (Philips, GE, Mindray, Dräger, Masimo, Nellcor, Nihon Kohden, ZOLL and others); "compatible with" does not imply any OEM, authorized or endorsement relationship with those brands. Any OEM partnership you enter is with MedLinket, under your own brand.
6. Real OEM project walkthrough — from inquiry to shipment
Short answer: a typical Tier 1 (brand-only) project runs about 45–60 days from inquiry to first shipment arrival. The workflow below shows the standard phases and the customer's responsibilities at each. Tier 2–3 add roughly 30–60 days for packaging design and configuration validation; Tier 4 joint development adds 9–18 months including regulatory cycles.
Tier 1 / Tier 2 standard project timeline
Customer submits an inquiry detailing target SKUs, destination market and expected annual volume. NDA signed. Physical samples ship within ~5–10 working days for testing.
The customer's clinical or BMET team tests adhesion, signal quality on the target monitor and packaging integrity. Optional: a third-party AAMI EC12 retest at the customer's expense for verification confidence.
Pricing tiers, MOQ, payment terms, Incoterms, regulatory ownership and exit clauses confirmed. Customer submits packaging design files and brand assets.
Packaging proofs prepared and approved. For Tier 2, packaging tooling is finalized; for Tier 3, product-level adjustments are validated.
First lot manufactured with in-line QC checkpoints and per-lot AAMI EC12 testing; EO sterilization validation for sterile variants. Pre-shipment inspection optional at the customer's expense.
Optional third-party container inspection. Bill of lading, certificate of origin, lot-level COA and customs documentation prepared.
Sea freight departs per Incoterms; air freight available for first orders or SKU lots needing a fast inventory ramp.
⚠️ Run regulatory registration in parallel. If your destination market requires registration in your name (e.g. NMPA, ANVISA), run that registration alongside the OEM production timeline — not after. Many first-time launches fail at exactly this point: product arrives but cannot be sold because approval is still pending. Plan for roughly 3–12 months of regulatory cycle depending on the market, and time your first order accordingly.
7. 9 common pitfalls for new private-label distributors
| Pitfall | Consequence | How to avoid |
|---|---|---|
| Launching 5+ SKUs at once | Inventory cash strain; can't tell which SKUs actually sell | Start with 2–3 core SKUs for the first 6 months; expand on performance data |
| Choosing the factory with the lowest MOQ | Low MOQ often signals small scale and capacity-stability risk | MOQ is not the primary criterion — regulatory and AAMI EC12 data are |
| Ordering bulk before sample testing | Performance shortfall found after payment; whole-shipment loss | Always test samples — including a third-party EC12 retest for a first-time supplier |
| Copying packaging from established brands | Trademark infringement; customs hold; legal action | Engage local IP counsel for trademark clearance; build an original brand identity |
| Letting product arrive before registration completes | Product can't be sold; warehouse cost; expiry risk | Run registration in parallel; ship after the expected approval date |
| Promising fast delivery with no buffer stock | Stockouts damage relationships; emergency air freight kills margin | Maintain a healthy safety stock (e.g. ~60 days of volume) |
| Skipping regional/SKU exclusivity | A competitor private-labels the same configuration in your territory | Negotiate territory or SKU-configuration exclusivity at signing |
| Using non-sterile general-ward variants in cath lab / imaging ICU | Clinical complaints; lost contract; brand damage | Specify carbon-snap (V0015) sterile (-S-) variants for imaging from launch |
| Ignoring early complaint data | Quality issues fester; renewal risk at year end | Monthly complaint-rate review with the manufacturer against an agreed threshold |
8. Self-assessment: are you ready for private label?
Short answer: eight yes/no questions that filter whether the move from agency to private label fits your business now, in two years, or not at all. The honest answer matters more than the optimistic one.
The 8-question filter
- Is my target-market monthly ECG electrode volume around 50,000 pieces or more (or projected to reach it within 12 months)?
- Do I have a regulatory-registration team, or a budget for outsourced regulatory services in my destination market?
- Do I have enough cash-flow runway to carry first-batch inventory plus registration costs?
- Do I have a customer-service operation that can handle quality complaints and field requests directly (not via the principal)?
- Can I commit to a first-order MOQ in the tens of thousands of pieces per SKU?
- Are my core hospital customers signaling demand for a private-label option (or am I confident they'll accept one)?
- Do I have a few years of direct experience in ECG electrodes or related monitoring consumables?
- Can I accept a ~60-day signing-to-shipment timeline, plus registration time on top?
✅ 7–8 yes: strong candidate — proceed with a Tier 1 evaluation and contract negotiation.
⚠️ 5–6 yes: proceed cautiously with Tier 1 (brand-only) on 2–3 SKUs to validate operational fit before higher tiers.
⚠️ 3–4 yes: consider 12–18 more months of agency selling first, addressing the specific gaps above.
❌ 0–2 yes: stay with agency arrangements for now; private label isn't the right move at this stage.
An honest note from MedLinket. We have declined OEM-partnership requests where we believed the distributor wasn't ready — usually because of insufficient regulatory capability or an undercapitalized inventory position. Pushing forward in those cases hurts both parties. We would rather support you as an agency partner for a couple of years and then onboard you as an OEM partner positioned to succeed.
Recommended path forward
Most successful private-label ECG electrode brand owners follow a three-stage progression:
- Stage 1 (Months 0–6): Tier 1 brand-only relabeling on 2–3 best-sellers (typically Φ50 mm metal-snap, 70.5 × 55 mm offset, Φ30 mm pediatric). Validate market acceptance, operational fit and cash-flow assumptions.
- Stage 2 (Months 6–18): Tier 2 packaging customization and SKU expansion to 5–8 variants, including V0015 carbon-snap for imaging-frequent customers. Establish a brand identity beyond the launch portfolio.
- Stage 3 (Year 2+): Tier 3 micro-customization for a differentiated portfolio; consider Tier 4 joint development only if a specific clinical requirement emerges that no existing product satisfies.
The progression typically takes 18–24 months. Skipping stages — especially jumping to Tier 3 or 4 before establishing Tier 1 operational fit — is the most common cause of stalled launches.
Request your OEM quote & capability pack
Receive the MedLinket OEM partnership documentation: the 4-tier capability brief; AAMI EC12 lot-level test reports; FDA 510(k), CE MDR, NMPA and MDSAP certification scans; an OEM project-timeline template; an NDA and standard OEM contract framework; a reference list (with contact permissions); the product-liability insurance certificate (coverage up to USD 5M, with a distributor-as-additional-insured option on request); and a pricing-tier framework based on your SKU set and annual volume.
📧 Email shopify@medlinket.com with your company name and country, category experience, intended SKU set, target annual volume and destination market(s).
💬 WhatsApp our OEM partnership team: +852 6467 3105
Browse Disposable ECG Electrodes → Request OEM Capability Pack →
9. Frequently asked questions
What's the difference between OEM and private label ECG electrodes?
In pure OEM, the buyer owns the product design and the factory manufactures to it. In private label, the factory's existing product is sold under the buyer's brand without design changes. Most distributors are operationally in private label or ODM (factory design plus the customer's brand and packaging) — pure OEM needs R&D and IP capabilities most distributors don't have at startup. Industry conversation conflates the terms; in a contract, what matters is who owns the design IP and who holds the regulatory clearance.
What's the typical MOQ for private label ECG electrodes?
As an industry reference: brand-only relabeling ~50,000–100,000 pieces/SKU; packaging customization ~100,000–300,000; product micro-customization within an existing platform ~500,000+; joint development 1,000,000+ with a multi-year commitment. MOQ scales with customization depth and the regulatory effort the manufacturer must invest. These are typical ranges, not a specific quotation.
Who holds the FDA 510(k) clearance for OEM ECG electrodes?
Either the manufacturer or the brand owner, depending on the agreement. The most cost-effective approach for new brands is usually for the manufacturer to hold the 510(k) and provide a Letter of Authorization to the brand owner, who acts as importer of record — avoiding the need to maintain a separate predicate-device file and submission infrastructure. The trade-off is dependence on the manufacturer's continued 510(k) maintenance. Confirm specifics with qualified regulatory counsel.
How long does it take to launch a private-label ECG electrode brand?
From inquiry to first shipment: roughly 45–90 days for brand-only relabeling or packaging customization; product micro-customization extends further; joint development with new biocompatibility testing and regulatory submissions typically runs 9–18 months. Destination-market registration in the brand owner's name (NMPA, ANVISA, etc.) can add roughly 3–12 months on top, and should run in parallel with manufacturing.
Can I customize the gel or adhesive in OEM ECG electrodes?
Yes — that falls under joint development. Custom gel or adhesive formulations require new biocompatibility testing under ISO 10993-5 (cytotoxicity), ISO 10993-10 (sensitization) and ISO 10993-23 (irritation), and typically trigger new 510(k) submissions, CE technical-file updates and new product registrations. It's appropriate when a specific differentiated clinical requirement — for example, an ultra-low-allergy variant for a sensitive-skin population — isn't met by any product already on the manufacturer's validated platform.
What's the typical pricing structure for OEM ECG electrodes?
Pricing follows volume tiers, and in practice the deepest discounts come from multi-year commitments with annual minimums rather than single-order size — manufacturers trade price for capacity-utilization predictability. Specific pricing depends on the SKU set, customization depth, destination-market regulatory cost and Incoterms, so request a quotation rather than relying on a fixed percentage.
Do I need to inspect the factory before signing?
Strongly recommended. At minimum, request a virtual tour with live video of production lines, cleanroom monitoring, the R&D lab and QC stations, plus the most recent ISO 13485 surveillance-audit summary and any FDA inspection observations. For larger commitments or any Tier 3–4 arrangement, on-site visits are standard practice — most counterfeit operations can't withstand on-site inspection. MedLinket's Shenzhen and Shaoguan facilities are open to qualified buyer visits.
Can I source from multiple OEM factories at once?
Yes — multi-factory sourcing is common for risk mitigation, especially for high-volume brand owners avoiding single-source exposure. The operational requirements: ensure each factory's product passes equivalent third-party AAMI EC12 testing, keep packaging consistent across sources to avoid end-customer confusion, and document lot identification clearly so complaints trace to the correct source. Unmanaged variability between manufacturers can confuse customers and damage brand reputation.
What if my country requires a local company to hold the registration?
Several markets — China (NMPA), Brazil (ANVISA) and others — require a local legal entity as the certificate holder. Brand owners typically (a) establish a local subsidiary, (b) partner with an in-country registration holder under a local-agent agreement, or (c) use a Marketing Authorization Holder service. Each has different cost, control and exit-flexibility profiles, and the structure should be settled before manufacturing begins.
How do I move from an agency arrangement to OEM with the same factory?
Many distributors begin as agency or compatible-product buyers and graduate to OEM/private label after 12–24 months of an established relationship. The transition is smoother because regulatory capability, manufacturing performance and service responsiveness are already proven. The decision points: confirm the OEM commercial structure (pricing, MOQ, exclusivity), establish an OEM-specific quality framework, and sequence the regulatory transitions in markets that require a change of registration holder.
10. References & standards
Performance & quality standards
- ANSI/AAMI EC12 — Disposable ECG Electrodes: AC impedance, DC offset, bias-current tolerance, defibrillation-overload recovery, combined offset instability and noise.
- ANSI/AAMI EC53 — ECG Cables and Leadwires: connector dimensional standards.
- ISO 13485:2016 — medical-device quality-management systems.
- ISO 10993-5, -10, -23 — biological evaluation: cytotoxicity, skin sensitization, skin irritation.
- ISO 11607-1, -2 — packaging for terminally sterilized medical devices (applicable to sterile-coded "-S-" pouches).
- EN ISO 11135 — sterilization of health-care products by ethylene oxide.
Regulatory references
- U.S. FDA 510(k) Premarket Notification — 21 CFR Part 807, Subpart E; ECG electrodes under Product Code DRX.
- U.S. FDA Letter of Authorization (LoA) — guidance on third-party reference of premarket submissions.
- EU MDR (2017/745) — Class IIa requirements; Authorized Representative (Article 11).
- NMPA (China) — local-legal-entity requirement for Class II registration.
- ANVISA RDC 751/2022 — Brazilian medical-device classification and registration.
- TGA Therapeutic Goods (Medical Devices) Regulations 2002 — Australian sponsor designation.
- MDSAP — Medical Device Single Audit Program (FDA, Health Canada, ANVISA, TGA, PMDA).
Internal references (available on request)
- MedLinket internal product specification documentation — V0014 (metal-snap) and V0015 (carbon-snap) series; SKU codes, dimensions, AAMI EC12-tested values, packaging configurations and 2-year shelf-life validation. Available via shopify@medlinket.com.
- MedLinket OEM service capability documentation — the 4-tier brief, project-timeline templates, pricing-tier framework and standard OEM contract templates. Available under NDA to qualified prospective partners.
- Patent CN202120112524.5 — the eccentric (offset) ECG electrode structural design, a granted utility-model patent, searchable in the CNIPA database; part of MedLinket's broader patent portfolio.
About MedLinket
MedLinket (Shenzhen Med-link Electronics Tech Co., Ltd) has specialised in capturing and transmitting vital biological signals since 2004. The company began OEM work in its earliest years, moved into its own-brand distribution around 2010, and was listed on China's New Third Board (NEEQ) in 2015 — described in company materials as the first listed company in the Chinese monitoring-consumables sector. Since around 2022 it has run a dual-track strategy of in-house brand plus OEM/ODM partnerships, supporting partner brands rather than competing with them in their served markets.
MedLinket holds ISO 13485:2016, ISO 9001:2015 and MDSAP certifications, with 33 NMPA Class II registrations in China plus FDA 510(k) clearances, CE marking under MDR 2017/745, and registrations across MHRA (UK), ANVISA (Brazil), TGA (Australia) and PMDA (Japan). Dual self-owned manufacturing sites in Shenzhen (HQ) and Shaoguan run a broad validated platform — on the order of 10,000+ product types across 2,800+ molds. The MedLinket V0014 (metal-snap) and V0015 (carbon-snap, radiolucent) ECG electrode series — including the patented eccentric (offset) thin-neck FPC structural design under utility-model patent CN202120112524.5 — supply more than 2,000 hospitals across over 110 countries, with 14 countries recording annual sales above USD 1 million. Product-liability insurance is carried across the product line up to USD 5 million, with a distributor-as-additional-insured option available on request during the policy period.
⚠️ OEM partnership & regulatory disclaimer. This article is for distributor and brand-owner education in evaluating OEM ECG electrode partnerships. It is not legal, regulatory, or commercial advice for any specific transaction. MOQ ranges, pricing tiers, timeline figures and regulatory descriptions are typical industry references and may not match specific MedLinket quotations or the requirements of any particular market. Regulatory ownership of 510(k) clearances, CE certificates and national registrations carries legal, tax, customs and product-liability consequences in every market. Always engage qualified medical-device regulatory counsel and commercial legal counsel familiar with your destination market before structuring or signing OEM agreements. Performance figures attributed to MedLinket are from internal product-specification and laboratory documentation; partner products may not be directly comparable unless tested under the same method and standard. "Compatible with" any monitor brand does not imply an OEM, authorized or endorsement relationship with that brand.
OEM/private-label node of MedLinket's ECG Electrodes content cluster. Last reviewed by the VP of Business Development, MedLinket OEM Partnership Team, on June 22, 2026.
